Zolgensma was initially approved in 2019 for the treatment of SMA, launching with a list price of $2.125m
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.